Clinical trials: Atorvastatin, completed
Dyslipidemia, Coronary Heart Disease
Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.
The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium…
- Conditions
- Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
- Trial name
- NCT00300430
- Testing
- ABT-335 and rosuvastatin calcium, ABT-335 and atorvastatin calcium, ABT-335 and simvastatin
- Where
- United States
- Volunteers
- 1,911 people
- Sponsor
- Abbott
Hypercholesterolemia
Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients as Monotherapy or in Combination With Atorvastatin
The primary purpose of this placebo-controlled study is to evaluate the low-density lipoprotein cholesterol (LDL-C) efficacy and dose-response of gemcabene 300, 600 and 900 mg/day administered as monotherapy or in combination…
- Trial name
- NCT02591836
- Testing
- Gemcabene, Atorvastatin
- Volunteers
- 277 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Healthy Subjects
Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Losartana + Hydrochlorothiazide
The objective of this clinical study, randomized, crossover is to evaluate the pharmacokinetic profile of the polypill (atorvastatin + lorsatana + hydrochlorothiazide) Laboratory Hypermarcas S / A, in relation to drugs Citalor ®…
- Trial name
- NCT01692717
- Testing
- Atorvastatin, Hydrochlorothiazide + Losartan, Hydrochlorothiazide + Losartan + Atorvastatin
- Where
- Brazil
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Medication Non-Adherence
Effectiveness Of A Program That Includes Counseling And Patient Support On Adherence To Treatment With Lipitor
Despite extensive reports of the benefits of statins in reducing serious cardiovascular events such as stroke and heart disease in patients with elevated LDL-cholesterol, patients do not take their medicines regularly as…
- Trial name
- NCT01078285
- Testing
- No Patient Counseling, Adherence Counseling
- Where
- 3 sites in United States
- Volunteers
- 500 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
- Trial name
- NCT01644188
- Testing
- Alirocumab, Ezetimibe, Lipid Modifying Therapy (LMT)
- Where
- 126 sites in United States, Canada and 8 more
- Volunteers
- 720 people
- Sponsor
- Sanofi
Dyslipidemia
A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337
This study is a randomized, open-label, single oral dose, 2-way crossover clinical trial to compare safety and pharmacokinetics of CKD-337 in healthy male volunteers.
- Trial name
- NCT02651753
- Testing
- Lipitor + Lipidil supra, CKD-337
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hyperlipidemia
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
This study is a multicenter, double blinded, active and placebo controlled randomized clinical trial to demonstrate a superior lipid lowering effect of Bococizumab (PF-04950615; RN316) compared to placebo in subjects who are…
- Trial name
- SPIRE-SI (NCT02135029)
- Testing
- Bococizumab (PF-04950615;RN316), Atorvastatin
- Where
- 40 sites in United States, Canada
- Volunteers
- 184 people
- Sponsor
- Pfizer
Healthy
Relative Bioavailability of Dabigatran and Atorvastatin in Healthy Male and Female Volunteers
To investigate the bioavailability of dabigatran with and without concomitant administration of atorvastatin and the bioavailability of atorvastatin with and without concomitant administration of dabigatran etexilate
- Trial name
- NCT02171039
- Testing
- Dabigatran, Atorvastatin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hypercholesterolemia, Atherosclerosis
Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)
To compare the efficacy of ezetimibe 10 mg added daily to ongoing treatment with atorvastatin 10 mg daily versus ezetimibe placebo added daily to ongoing treatment with atorvastatin 10 mg daily in reducing the concentration of…
- Trial name
- NCT00651404
- Testing
- Ezetimibe
- Volunteers
- 137 people
- Sponsor
- Organon and Co
Dyslipidemia
An Observational Study to Evaluate the Treatment of Newvast® Tab(Atorvastatin) in Korean Patients With Dyslipidemia
In this study, dyslipidemia patients visited the institutions during the study period and the effectiveness and safety of the treatment of Newvast® Tab(Atorvastatin) in real-practice.
- Trial name
- NCT05555238
- Testing
- single arm, single group(No interventional)
- Where
- South Korea
- Volunteers
- 1,716 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension, Dyslipidemia
Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia
To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines.
- Trial name
- JEWEL I (NCT00330785)
- Testing
- Amlodipine/Atorvastatin
- Where
- 126 sites in Canada, United Kingdom
- Volunteers
- 1,250 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia
Special Drug Use-Results Survey of Lipitor Tablets
This study is to evaluate the controlling effect of atrovastatin on plasma lipid to achieve the category-specific targeted lipid levels.
- Trial name
- ALWAYS (NCT01446679)
- Testing
- atrovastatin
- Where
- 8 sites in Japan
- Volunteers
- 24,050 people
- Sponsor
- Astellas Pharma Inc
Hypercholesterolemia
Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
To determine the efficacy, long-term safety, and tolerability of alirocumab 300 mg every 4 weeks (Q4W), in comparison with placebo, as well as its potential as a starting regimen.
- Trial name
- NCT01926782
- Testing
- Alirocumab, Statin
- Where
- 83 sites in United States, Bulgaria and 6 more
- Volunteers
- 803 people
- Sponsor
- Regeneron Pharmaceuticals
Healthy
CKD-337(2) Drug-drug Interaction Study
The purpose of this study is to evaluate the pharmacokinetic interaction between Atorvastatin and Fenofibric acid.
- Trial name
- NCT02422030
- Testing
- Lipitor Tab. 40mg, Trilipix 135mg
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Mixed Hyperlipidemia
Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)
This is a 12-week clinical trial in participants with mixed hyperlipidemia to study the effects of MK-0524B on lipids.The primary hypothesis is that MK-0524B (dosed as MK-0524A coadministered with simvastatin) will be superior to…
- Trial name
- NCT00289900
- Testing
- MK-0524A, Atorvastatin, Simvastatin
- Volunteers
- 2,340 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension, Hyperlipidemia
Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels
The purpose of the study is to measure the effect of the amlodipine/atorvastatin combination pill in reducing both elevated blood pressure and cholesterol levels to levels suggested by guidelines
- Trial name
- GEMINI-AALA (NCT00143234)
- Testing
- Amlodipine/atorvastatin single pill
- Where
- 118 sites in Argentina, Australia and 25 more
- Volunteers
- 1,825 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension, Hypercholesterolemia
Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients
The primary objective is to investigate the safety of Caduet (2.5 mg/5 mg, 2.5 mg/10 mg, 5 mg/5 mg or 5 mg/10 mg as dose of Amlodipine/Atorvastatin) during 52 weeks treatment period in Japanese patients with both of hypertension…
- Conditions
- Hypertension, Hypercholesterolemia, Angina Pectoris
- Trial name
- NCT01190007
- Testing
- Caduet
- Where
- 20 sites in Japan
- Volunteers
- 159 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hyperlipidemia
A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. A study to look at lipid levels in subjects taking the study drug, Atorvastatin alone or placebo.
- Trial name
- NCT00138762
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 154 sites in United States, Belgium and 6 more
- Volunteers
- 3,800 people
- Sponsor
- Pfizer
Coronary Arteriosclerosis, Hypercholesterolemia
Comparative Atorvastatin Pleiotropic Effects
The primary objective of the study is to evaluate the efficacy of atorvastatin 80 mg daily as compared to atorvastatin 10 mg daily in reducing C-reactive protein levels over a 26-week treatment period in subjects with documented…
- Trial name
- CAP (NCT00163202)
- Testing
- Blood samples, Atorvastatin
- Where
- 74 sites in Canada, Czechia and 5 more
- Volunteers
- 330 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension, Hypercholesterinemia
A Study to Evaluate Drug-drug Interactions Between BR1017-1 and BR1017-2 in Healthy Volunteers
To evaluate the influence of BR1017-1 and BR1017-2 on pharmacokinetics and safety when administered separately or co-administered to healthy volunteers.
- Trial name
- NCT05372380
- Testing
- BR1017-1, BR1017-2
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd